 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | autologous CD7-CAR T cells / Beijing Boren Hospital
Trial primary completion date, CAR T-Cell Therapy: Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov) - Aug 15, 2022
P1, N=20, Recruiting, Sponsor: Beijing Boren Hospital
Trial primary completion date: Apr 2022 --> Apr 2023
- autologous CD7-CAR T cells / Beijing Boren Hospital
Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma. (Available On Demand; 266) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4272;
P1
Autologous CD7 CAR T cell therapy was safe and effective in the induction of remission in r/r T-ALL/LBL patients, without signs of GVHD. Longer follow-up time of more cases will be used to further evaluate this therapy.
- | autologous CD7-CAR T cells / Beijing Boren Hospital
New P1 trial, CAR T-Cell Therapy: Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov) - Apr 12, 2021
P1, N=20, Recruiting, Sponsor: Beijing Boren Hospital